Cargando…

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient

Despite decades of research and clinical trials, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and typically fatal. Current treatments may provide modest increases in progression-free survival but can come with significant adverse effects and are disaggregated from the di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parker, David, Zambelli, Jessica, Lara, Montana Kay, Wolf, Trevor Hamilton, McDonald, Amber, Lee, Erica, Abou-Elkacem, Lotfi, Gordon, Eva J., Baum, Richard P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175697/ https://www.ncbi.nlm.nih.gov/pubmed/37188199 http://dx.doi.org/10.3389/fonc.2023.1192792

Ejemplares similares

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
por: Kostos, Louise, et al.
Publicado: (2023)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
por: Langbein, Thomas, et al.
Publicado: (2022)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022)

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
por: Rizzo, Alessio, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Outcome of (177)Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2021)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
por: Hoshi, Seiji, et al.
Publicado: (2023)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

Salvage Radioligand Therapy with Repeated Cycles of (177)Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
por: Groener, Daniel, et al.
Publicado: (2021)

(177)Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
por: Bu, Ting, et al.
Publicado: (2022)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a5dggeles67osp4abhhm1eiefa